Upfront PSMA Alliance
Upfront PSMA Alliance: Using theranostics early to eradicate prostate cancer and developing novel strategies for PSMA-negative disease
The first aim of the study will be to conduct an Australian wide randomised phase II study in patients with newly diagnosed metastatic prostate cancer. The study will compare whether the addition of LuPSMA to the current standard-of-care of androgen deprivation therapy and chemotherapy will improve patient outcomes.
In a second aim, patients with high-risk localised prostate cancer will be given LuPSMA prior to undergoing a radical prostatectomy. Scanning and pathology findings will be evaluated to see whether this is a successful strategy to reduce recurrence rates.
Investigators
|
A/Prof Arun Azad |
Peter MacCallum Cancer Centre and University of Melbourne |
| Prof Michael Hofman (Co PI) |
Peter MacCallum Cancer Centre and University of Melbourne |
| Dr Ian Vela (Team member) |
APCRC-Q, IHBI, QUT, TRI |
Administering Institution
Peter MacCallum Cancer Centre
Duration
2019 - 2021
Funding
| Cancer Australia and Movember Foundation | $5 400 000 |
